Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

Population effects of preventive and therapeutic HIV vaccines in early- and late-stage epidemics.

Owens DK, Edwards DM, Shachter RD.

AIDS. 1998 Jun 18;12(9):1057-66.

PMID:
9662203
2.

Stochastic simulation of the impact of antiretroviral therapy and HIV vaccines on HIV transmission; Rakai, Uganda.

Gray RH, Li X, Wawer MJ, Gange SJ, Serwadda D, Sewankambo NK, Moore R, Wabwire-Mangen F, Lutalo T, Quinn TC; Rakai Project Group.

AIDS. 2003 Sep 5;17(13):1941-51.

PMID:
12960827
3.

Model-based optimization of infectivity parameters: a study of the early epidemic in San Francisco.

Ahlgren DJ, Gorny MK, Stein AC.

J Acquir Immune Defic Syndr. 1990;3(6):631-43.

PMID:
2338619
4.

Knowledge about vaccines and willingness to participate in preventive HIV vaccine trials: a population-based study, Rakai, Uganda.

Kiwanuka N, Robb M, Kigozi G, Birx D, Philips J, Wabwire-Mangen F, Wawer MJ, Nalugoda F, Sewankambo NK, Serwadda D, Gray RH.

J Acquir Immune Defic Syndr. 2004 Jun 1;36(2):721-5.

PMID:
15167291
5.

Forecasting the future of HIV epidemics: the impact of antiretroviral therapies & imperfect vaccines.

Blower S, Schwartz EJ, Mills J.

AIDS Rev. 2003 Apr-Jun;5(2):113-25. Review.

PMID:
12876900
6.

The cost-effectiveness of a modestly effective HIV vaccine in the United States.

Long EF, Owens DK.

Vaccine. 2011 Aug 18;29(36):6113-24. doi: 10.1016/j.vaccine.2011.04.013. Epub 2011 Apr 19.

7.

Predictive value of primate models for AIDS.

Haigwood NL.

AIDS Rev. 2004 Oct-Dec;6(4):187-98. Review.

PMID:
15700617
8.
9.

Modelling the impact of antiretroviral use in resource-poor settings.

Baggaley RF, Garnett GP, Ferguson NM.

PLoS Med. 2006 Apr;3(4):e124. Epub 2006 Mar 14.

10.

Assessing the attitudes, knowledge, and awareness of HIV vaccine research among adults in the United States.

Allen MA, Liang TS, La Salvia T, Tjugum B, Gulakowski RJ, MurguĂ­a M.

J Acquir Immune Defic Syndr. 2005 Dec 15;40(5):617-24.

PMID:
16284540
11.
12.

The potential impact of a moderately effective HIV vaccine with rapidly waning protection in South Africa and Thailand.

Andersson KM, Stover J.

Vaccine. 2011 Aug 18;29(36):6092-9. doi: 10.1016/j.vaccine.2011.06.060. Epub 2011 Jun 22.

PMID:
21703322
14.

Reconstruction of human immunodeficiency virus (HIV) sub-epidemics in Italian regions.

Barcherini S, Cantoni M, Grossi P, Verdecchia A.

Int J Epidemiol. 1999 Feb;28(1):122-9.

15.

Simulating the effect of vaccine-induced immune responses on HIV infection.

Guardiola J, Izzo G, Vecchio A.

Hum Immunol. 2003 Sep;64(9):840-51.

PMID:
12941538
16.
17.

Cost-effectiveness of the Mpowerment Project, a community-level intervention for young gay men.

Kahn JG, Kegeles SM, Hays R, Beltzer N.

J Acquir Immune Defic Syndr. 2001 Aug 15;27(5):482-91.

PMID:
11511826
18.

Role of CCL3L1-CCR5 genotypes in the epidemic spread of HIV-1 and evaluation of vaccine efficacy.

Kulkarni H, Marconi VC, Agan BK, McArthur C, Crawford G, Clark RA, Dolan MJ, Ahuja SK.

PLoS One. 2008;3(11):e3671. doi: 10.1371/journal.pone.0003671. Epub 2008 Nov 7.

19.

Studying dynamics of the HIV epidemic: population-based data compared with sentinel surveillance in Zambia.

Fylkesnes K, Ndhlovu Z, Kasumba K, Mubanga Musonda R, Sichone M.

AIDS. 1998 Jul 9;12(10):1227-34.

PMID:
9677172
20.

Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectiveness.

Desai K, Sansom SL, Ackers ML, Stewart SR, Hall HI, Hu DJ, Sanders R, Scotton CR, Soorapanth S, Boily MC, Garnett GP, McElroy PD.

AIDS. 2008 Sep 12;22(14):1829-39. doi: 10.1097/QAD.0b013e32830e00f5.

PMID:
18753932
Items per page

Supplemental Content

Write to the Help Desk